Cancer Moonshot initiative, the USPTO is extending the program, with all parameters remaining the same, until September 30, 2022. The USPTO is also in the process of deciding whether to expand the scope of the pilot program and may, additionally, further extend it (with or without modifications), depending on feedback from the participants and the public, additional continued interest, and the program’s effectiveness.

DATES: Comments must be received by July 29, 2022 to ensure consideration.

Pilot duration: The Cancer Immunotherapy Pilot Program will continue to run until September 30, 2022. Therefore, petitions to make special under the Cancer Immunotherapy Pilot Program must be filed on or before September 30, 2022.

ADDRESSES: For reasons of Government efficiency, comments must be submitted through the Federal eRulemaking Portal at www.regulations.gov. To submit comments via the portal, enter docket number PTO–P–2022–0019 on the homepage and click “Search.” The site will provide a search results page listing all documents associated with this docket. Find a reference to this notice and click on the “Comment Now!” icon, complete the required fields, and enter or attach your comments. Attachments to electronic comments will be accepted in ADOBE® portable document format or MICROSOFT WORD® format. Because comments will be made available for public inspection, information that the submitter does not desire to make public, such as an address or phone number, should not be included in the comments.

Visit the Federal eRulemaking Portal website (www.regulations.gov) for additional instructions on providing comments via the portal. If electronic submission of comments is not feasible due to a lack of access to a computer and/or the internet, please contact the USPTO using the contact information below for special instructions.

FOR FURTHER INFORMATION CONTACT: For questions regarding this pilot program in general, please contact Susy Tsang-Foster, Senior Legal Advisor, Office of Patent Legal Administration, Office of the Deputy Commissioner for Patent Examination Policy, at 571–272–7711 or susy.tsang-foster@uspto.gov. For questions related to a particular petition, please contact Gary B. Nickol, Supervisory Patent Examiner, at 571–272–0835 or gary.nickol@uspto.gov; or Brandon J. Fetterolf, Supervisory Patent Examiner, at 571–272–2919 or brandon.fetterolf@uspto.gov, both of Technology Center 1600.

SUPPLEMENTARY INFORMATION: On June 29, 2016, the USPTO published a notice for the implementation of the Cancer Immunotherapy Pilot Program. See Cancer Immunotherapy Pilot Program, 81 FR 42328 (Cancer Immunotherapy Notice). The pilot program was designed to support the global fight against cancer. The Cancer Immunotherapy Notice indicated that an applicant could have an application advanced out of turn (accorded special status) for examination without meeting all the current requirements of the accelerated examination program set forth in item VIII of section 708.02(a) of the Manual of Patent Examining Procedure if the application contained at least one claim to a method of treating a cancer using immunotherapy and the applicant met other requirements specified in the Cancer Immunotherapy Notice.

The Cancer Immunotherapy Notice established that the pilot program would run for 12 months, beginning on June 29, 2016. Over the course of the pilot program, the USPTO has extended it through notices published in the Federal Register. The most recent notice extended the program until June 30, 2022. See Extension of the Cancer Immunotherapy Pilot Program, 85 FR 41570 (July 10, 2020). In view of the continued interest in the pilot program, the USPTO is hereby extending it through September 30, 2022. The extension will also allow the USPTO to continue its evaluation of the program. The requirements of the pilot program have not been modified.

Various stakeholders from around the world—including independent inventors, universities, research institutions, hospitals, medical centers, government agencies, and large and small companies—have filed petitions to participate in the pilot program. To date, over 835 petitions requesting participation have been filed, and over 615 patents have been granted under the pilot program.

The USPTO is currently deciding whether to expand the scope of the pilot program. The USPTO may further extend the program (with or without modifications), depending on feedback from the participants, additional continued interest, and the program’s effectiveness. The USPTO welcomes public comment on these topics.

Katherine K. Vidal,
Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office.

[FR Doc. 2022–13908 Filed 6–28–22; 8:45 am]

BILLING CODE 3510–P

COMMODITY FUTURES TRADING COMMISSION

Energy and Environmental Markets Advisory Committee; Request for Nominations

AGENCY: Commodity Futures Trading Commission.

ACTION: Notice.

SUMMARY: The Commodity Futures Trading Commission (CFTC or Commission) is requesting nominations for Associate Members of the Energy and Environmental Markets Advisory Committee (EEMAC or Committee) and also inviting the submission of potential topics for discussion at future Committee meetings. The EEMAC is an advisory committee established by the Dodd-Frank Wall Street Reform and Consumer Protection Act.

DATES: The deadline for the submission of nominations and topics is July 13, 2022.

ADDRESSES: Nominations and topics for discussion at future EEMAC meetings should be emailed to EEMAC_Submissions@cftc.gov or sent by hand delivery or courier to Chris Lucas, Chief of Staff to Commissioner Summer K. Mersinger, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street NW, Washington, DC 20581. Please use the title “Energy and Environmental Markets Advisory Committee” for any nominations or topics you submit.

FOR FURTHER INFORMATION CONTACT: Lauren Fulks, EEMAC Secretary, (816) 960–7719 or email: lfulks@cftc.gov.

SUPPLEMENTARY INFORMATION: The EEMAC was established to conduct public meetings; submit reports and recommendations to the Commission; and otherwise serve as a vehicle for discussion and communication on matters of concern to exchanges, trading firms, end users, energy producers, and regulators regarding energy and environmental markets and their regulation by the Commission.

Pursuant to the EEMAC’s authorizing statute, the EEMAC must have nine members. In addition, the EEMAC Charter requires that the Committee have approximately 9–20 Associate Members. The EEMAC currently has twelve Associate Members and Commissioner Summer K. Mersinger, the EEMAC’s Sponsor, seeks additional Associate Members of the EEMAC.

Accordingly, the Commission invites the submission of nominations for EEMAC Associate Members who represent a wide diversity of opinions and a broad spectrum of interests.
CONSUMER PRODUCT SAFETY COMMISSION

[Docket No. CPSC–2010–0038]

Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Testing of Children’s Products

AGENCY: Consumer Product Safety Commission.

ACTION: Notice.

SUMMARY: In accordance with the requirements of the Paperwork Reduction Act (PRA) of 1995, the Consumer Product Safety Commission (CPSC) announces that the CPSC has submitted to the Office of Management and Budget (OMB) a request for extension of approval of a collection of information for Third Party Testing of Children’s Products, approved previously under OMB Control No. 3041–0159. In the Federal Register of April 13, 2022, the CPSC published a notice to announce the agency’s intention to seek extension of approval of the collection of information. The Commission did not receive any comments on the proposed extension of approval. By publication of this notice, the Commission announces that CPSC has submitted to the OMB a request for extension of approval of that collection of information, without change.

DATES: Submit written or electronic comments on the collection of information by July 29, 2022.

ADDRESSES: Submit comments about this request by email: OIRA_submission@omb.eop.gov or fax: 202–395–6881. Comments by mail should be sent to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for the CPSC, Office of Management and Budget, Room 10235, 725 17th Street NW, Washington, DC 20503. In addition, written comments that are sent to OMB, also should be submitted electronically at: http://www.regulations.gov, under Docket No. CPSC–2010–0038.

FOR FURTHER INFORMATION CONTACT: Cynthia Gillham, Consumer Product Safety Commission, 4330 East West Highway, Bethesda, MD 20814; (301) 504–7791, or by email to: cgillham@cpsc.gov.

SUPPLEMENTARY INFORMATION: CPSC seeks to renew the following currently approved collection of information: Title: Third Party Testing of Children’s Products. OMB Number: 3041–0159. Type of Review: Renewal of collection of information for third party testing of children’s products, which includes: (1)